Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | STAT1 | P42224 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.37 |
| ▸ | RELA | Q04206 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257425 | 0.78 | MAPT (0.62) | KDM4ENPC1RAB9AALDH1A1MAPT | |
| SCHEMBL2899853 | 0.72 | KMT2A (0.52) | KDM4ENPC1RAB9AALDH1A1MAPT | |
| SCHEMBL29923403 | 0.65 | PLAU (0.60) | KDM4ENPC1RAB9AALDH1A1MAPT | |
| SCHEMBL199273 | 0.65 | PLAU (0.60) | KDM4ENPC1RAB9AALDH1A1MAPT | |
| SCHEMBL6651977 | 0.65 | KDM4A (0.46) | KDM4ENPC1RAB9AALDH1A1MAPT | |
| SCHEMBL30522769 | 0.64 | PLAU (0.58) | KDM4ENPC1RAB9AALDH1A1MAPT | |
| SCHEMBL934818 | 0.63 | KDM4E (0.50) | KDM4EHTTNPC1RAB9AALDH1A1 | |
| SCHEMBL15775443 | 0.63 | RAB9A (0.49) | KDM4ENPC1RAB9AALDH1A1MAPT | |
| SCHEMBL29610252 | 0.63 | RAB9A (0.49) | KDM4ENPC1RAB9AALDH1A1MAPT | |
| SCHEMBL11934963 | 0.62 | PTPN2 (0.51) | KDM4EHTTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322815-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | UNIVERSITY OF HUDDERSFIELD (GB) | 2023-10-12 | — | — | US | disclosed |
| US-20230322815-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | UNIVERSITY OF HUDDERSFIELD (GB) | 2023-10-12 | — | — | US | disclosed |
| WO-2022034313-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | UNIVERSITY OF HUDDERSFIELD (GB) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322815-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | BRCA1, TPX2, XPA | KDM4E 3896/4885GAA 668/4885HTT 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.